Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood (2024) 144 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2024-206169

Published: 2024

Journal Articles

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Blood (2024) 144 (Supplement 1): 4935.

https://doi.org/10.1182/blood-2024-210956

Published: 2024

Journal Articles

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2023-187460

Published: 2023

Journal Articles

Single Center Retrospective Study of Midostaurin Plus Intensive Chemotherapy for Older Patients with Newly Diagnosed FLT-3 Mutated Acute Myelogenous Leukemia

Blood (2023) 142 (Supplement 1): 5937.

https://doi.org/10.1182/blood-2023-173978

Published: 2023

Journal Articles

Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 10449–10450.

https://doi.org/10.1182/blood-2022-165839

Published: 2022

Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 774–776.

https://doi.org/10.1182/blood-2022-167626

Published: 2022

Journal Articles

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 12819–12820.

https://doi.org/10.1182/blood-2022-164657

Published: 2022

Journal Articles

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 10568–10570.

https://doi.org/10.1182/blood-2022-163652

Published: 2022

Journal Articles

Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 7595–7596.

https://doi.org/10.1182/blood-2022-170655

Published: 2022

Journal Articles

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 4821–4822.

https://doi.org/10.1182/blood-2022-164639

Published: 2022

Journal Articles

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Blood (2022) 139 (25): 3605–3616.

https://doi.org/10.1182/blood.2022015423

Published: 2022

Includes: Supplemental data

Journal Articles

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

Blood (2021) 138 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2021-154187

Published: 2021

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MDPhD, Ni-Chun Tsai, MS, Joycelynne Palmer, PhD, Xochiquetzal U. Martinez, MD, Farah Abdulla, MD, Xiwei Wu, PhD, Steven T. Rosen, MD, Jasmine Zain, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-143354

Published: 2020

Journal Articles

Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases

Nicole Karras, MD, Ni-Chun Tsai, MS, Ahmed Tahoun, MD, Saloomeh Mokhtari, Haris Ali, MD, Shukaib Arslan, MD, Anna B Pawlowska, MD, Chatchada Karanes, Joseph Rosenthal, MD MS, David S Snyder, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141334

Published: 2020

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141469

Published: 2020

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, PhD, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, MS, David Yamauchi, MD, Erasmus Kofi Poku, PharmD, Van Eric Biglang-awa, PharmD, John E. Shively, PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-141114

Published: 2020

Journal Articles

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

Monzr M. Al Malki, MD, Ni-Chun Tsai, MS, Joycelynne Palmer, PhD, Saloomeh Mokhtari, Thai Cao, MD, Haris Ali, MD, Amandeep Salhotra, MD, Shukaib Arslan, MD, Ibrahim Aldoss, MD, Nicole Karras, MD, Haris M. Ali, MD, Haris Ali, MD, Anthony S. Stein, MD, David S Snyder, MD, Guido Marcucci, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-142807

Published: 2020

Journal Articles

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Robert W. Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, Matthew Mei, MD, Leslie L. Popplewell, MD FRCPA, Auayporn P. Nademanee, MDBS, Liana Nikolaenko, MD, Kathryn McBride, Ricardo Ortega, Joo Y. Song, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Stephen J Forman, MD, Hun Ju Lee, MD

Blood (2019) 134 (Supplement_1): 239.

https://doi.org/10.1182/blood-2019-123162

Published: 2019

Journal Articles

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, Ni-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Ibrahim Aldoss, MD, Vinod A. Pullarkat, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 5729.

https://doi.org/10.1182/blood-2019-131437

Published: 2019

Journal Articles

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Amandeep Salhotra, MD, Liana Nikolaenko, MD, Lu Chen, PhD, NI-Chun Tsai, PhD, Diane Lynne Smith, PhD, Auayporn P. Nademanee, MDBS, Leslie L. Popplewell, MD FRCPA, Alex F. Herrera, MD, Matthew Mei, MD, Stephen J. Forman, MD, Jasmine M. Zain, MD

Blood (2019) 134 (Supplement_1): 4623.

https://doi.org/10.1182/blood-2019-131357

Published: 2019

NARROW

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Single Center Retrospective Study of Midostaurin Plus Intensive Chemotherapy for Older Patients with Newly Diagnosed FLT-3 Mutated Acute Myelogenous Leukemia

Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only